

Our ref: IG/FOI/FOI.584.25

4 December 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 14 November 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) partially holds the information that you require.

For ease of reference your request is set out below and the Health Board's response follows.

Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information:

Q1. Within your Trust, how many patients in total were admitted as inpatients between July – October 2025 with a primary cause of admission being a chronic obstructive pulmonary disease (COPD) exacerbation (ICD-10: J44.1)?

Q2. Of the patients admitted with a primary COPD exacerbation (ICD-10: J44.1) identified in Q1, how many were already prescribed a closed triple therapy* at the point of admission?

*Closed triple therapy = Trelegy, Trixeo, or Trimbaw (any formulation)

*"Already prescribed" means the therapy was documented as active on admission, either from hospital records or patient-reported history.

Q3. How many patients in total were prescribed Trixeo for COPD (ICD-10: J44.1) between July – October 2025?

How many of these were new to Trixeo*?

*New to Trixeo = Patient not prescribed Trixeo in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trixeo—whether prescribed in hospital or community settings—at the point of admission.

Q4. How many patients in total were prescribed Trimbow MDI (for COPD [ICD-10: J44.1]) between July – October 2025?

- How many of these were new to Trimbow MDI*?
- Of the new Trimbow MDI patients*, what was the split between:
- Trimbow MDI 87/5/9
- Trimbow MDI 172/5/9

*New to Trimbow MDI = Patient not prescribed Trimbow MDI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow MDI—whether prescribed in hospital or community settings—at the point of admission.

Q5. How many patients in total were prescribed Trelegy for COPD (ICD-10: J44.1) between July – October 2025?

How many of these were new to Trelegy*?

*New to Trelegy = Patient not prescribed Trelegy in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trelegy—whether prescribed in hospital or community settings—at the point of admission.

Q6. How many patients in total were prescribed Trimbow DPI (for COPD [ICD-10: J44.1]) between July – October 2025?

How many of these were new to Trimbow DPI*?

*New to Trimbow DPI = Patient not prescribed Trimbow DPI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow DPI—whether prescribed in hospital or community settings—at the point of admission

Powys Response:

Q1. I can confirm that there were 2 patients admitted between 1 July 2025 – 31 October with a primary diagnosis of J441.

Q2-Q6. I can confirm that we do not hold the data required to answer these questions. Primary care prescribing data in Wales is accessed via the national Comparative Analysis System for Prescribing Audit (CASPA), which provides aggregate prescribing quantities only. It does not include:

- patient-level prescribing data
- indication-level data (e.g. COPD vs other respiratory diagnoses)
- information on whether a patient was “new” to a medicine
- data linked to hospital admission dates or history

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future

communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>

Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.


Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



David Farnsworth
Assistant Director, Community Services Group



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.